CI
ALXN

CX Institutional’s Alexion Pharmaceuticals ALXN Stock Holding History

CX Institutional’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-452
Closed -$83K – 989
2021
Q2 		$83K Buy
452
+140
+45% +$24K 0.01% 469
2021
Q1 		$48K Buy
312
+48
+18% +$7.42K ﹤0.01% 502
2020
Q4 		$41K Buy
264
+78
+42% +$10K ﹤0.01% 478
2020
Q3 		$21K Buy
186
+55
+42% +$5.93K ﹤0.01% 538
2020
Q2 		$15K Buy
131
+71
+118% +$7.54K ﹤0.01% 508
2020
Q1 		$5K Sell
60
-21
-26% -$2.06K ﹤0.01% 564
2019
Q4 		$9K Buy
81
+53
+189% +$5.67K ﹤0.01% 450
2019
Q3 		$3K Sell
28
-30
-52% -$3.38K ﹤0.01% 707
2019
Q2 		$8K Sell
58
-50
-46% -$6.44K ﹤0.01% 539
2019
Q1 		$15K Buy
+108
New +$13.4K ﹤0.01% 423

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

CX Institutional's ALXN Position: Q3 2021 in Review

CX Institutional sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 452 shares — an estimated $83K sold.

CX Institutional first reported a position in ALXN in Q1 2019 and held it in 10 quarters. The position peaked at $83K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • CX Institutional reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • CX Institutional sold 452 Alexion Pharmaceuticals shares in Q3 2021, an estimated $83K.
  • CX Institutional first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • CX Institutional's Alexion Pharmaceuticals position peaked at $83K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on CX Institutional's 13F filing for Q3 2021, filed 10 Nov 2021.